



(11) **EP 1 222 929 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
A61K 39/395 (2006.01) A61P 7/02 (2006.01)

(48) Corrigendum issued on:
07.07.2010 Bulletin 2010/27

(45) Date of publication and mention
of the grant of the patent:
19.05.2010 Bulletin 2010/20

(21) Application number: **02447005.6**

(22) Date of filing: **11.01.2002**

(54) **Method and pharmaceutical composition for preventing and/or treating systemic inflammatory response syndrome**

Verfahren und pharmazeutische Zusammensetzung zur Vorbeugung und/oder Behandlung des Syndroms der systemischen entzündlichen Reaktion

Procédé et composition pharmaceutique pour la prévention et/ou le traitement du syndrome de réponse inflammatoire systémique

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**

(30) Priority: **11.01.2001 US 261405 P**

(43) Date of publication of application:
17.07.2002 Bulletin 2002/29

(73) Proprietor: **Life Sciences Research Partners VZW
3000 Leuven (BE)**

(72) Inventors:
• **Jacquemin, Marc G.
5330 Sart-Bernard (BE)**
• **Saint-Remy, Jean-Marie R.
1390 Grez-Doiceau (BE)**

(74) Representative: **Bird, William Edward et al
Bird Goën & Co.
Klein Dalenstraat 42A
3020 Winksele (BE)**

(56) References cited:
WO-A-01/04269 WO-A-97/26010

- **JACQUEMIN M ET AL: "A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor" BLOOD, W.B.SAUNDERS COMPAGNY, ORLANDO, FL, US, vol. 95, no. 1, 1 January 2000 (2000-01-01), pages 156-163, XP002150704 ISSN: 0006-4971**
- **JACQUEMIN M G ET AL: "MECHANISM AND KINETICS OF FACTOR VIII INACTIVATION: STUDY WITH AN IGG4 MONOCLONAL ANTIBODY DERIVED FROM A HEMOPHILIA A PATIENT WITH INHIBITOR" BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 92, no. 2, 1998, pages 496-506, XP000906844 ISSN: 0006-4971**
- **SAINT-REMY JEAN-MARIE R: "B- and T-cell tolerance: From basic concepts to clinical practice." HAEMATOLOGICA, vol. 85, no. 10 Suppl., October 2000 (2000-10), pages 93-96, XP008006242 ISSN: 0390-6078**

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 222 929 B8